| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Dept of Medicine and Physiology, Indiana University School of Med, Indianapolis, Indiana, United States
2 Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States
3 Department of Physiology and Biophysics, Indiana University School of Medicine, Indianapolis, Indiana, United States
* To whom correspondence should be addressed. E-mail: jhdoming{at}iupui.edu.
Anomalous inflammatory responses triggered by the metabolic syndrome cause renal injury. This discovery links renal lipid accumulation with lipotoxicity to inflammation, and may explain the insidious fibrosis and cellular decay characteristic of nephropathy in the metabolic syndrome. However, it is not clear if control of inflammation protects the kidney independently of lipid accumulation, which is a required step for lipotoxicity in hyperglycemia and dyslipidemia. We hypothesized that in rats with the metabolic syndrome, and overt nephropathy, treatment with mycophenolate mofetil (MMF, 10 mg/kg/day for 14 weeks, I.P.) would reduce the abnormal renal lipid depots and limit renal inflammation and injury. We studied groups of lean and obese F1 hybrid Zucker Fatty Diabetic/Spontaneous Hypertensive Heart Failure (ZS) rats. MMF did not affect lean rats. In obese ZS rats, MMF did not change severe hyperglycemia or the higher kidney loads of unutilized lipid and peroxidation products. Nonetheless, MMF dramatically reduced diabetes/obesity-derived systemic and renal inflammation, limited renal size, hyperfiltration, and fibrosis. These data indicate that in rats, anti-inflammatory therapy presumably acting downstream, and independently of lipotoxicity, can effectively limit renal injury and fibrosis.
This article has been cited by other articles:
|
|
 |
|
  A. G. Goodwill, M. E. James, and J. C. Frisbee Increased vascular thromboxane generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with reduced oxygen tension Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1522 - H1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Kelly, P. Wu, C. E. Patterson, C. Temm, and J. H. Dominguez LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1136 - F1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Dominguez, J. L. Mehta, D. Li, P. Wu, K. J. Kelly, C. S. Packer, C. Temm, E. Goss, L. Cheng, S. Zhang, et al. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations Am J Physiol Renal Physiol, January 1, 2008; 294(1): F110 - F119. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
